Pricing Log in Create free account
Sunday 18 October 2026 Export PRLD’s income statement to Excel — free account

Prelude Therapeutics Incorporated

PRLD Healthcare Biotechnology

Prelude Therapeutics Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $12.1 million, up 73.4% from fiscal 2024. In the quarter to June 2026, revenue grew 42.6%, EPS grew 65.9% and free cash flow grew 40.3%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

3.26 0.06 −1.81%
Market cap
$265.0M
P/E
0.0×
Fwd P/E
−16.6×
Dividend yield
—
F-score
n/a
Altman Z
−6.83
Beneish M
n/a
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 25.00
Totals in millions of $.
Dec 25 Mar 26 Jun 26 Sep 26
Buy — — — — — 2 — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership 54.54%

Capital & Financial Ratios $m

Market Cap 264.95
Revenue 22.42
Net Income (60.49)
Free Cash Flow (33.25)
Net Debt (151.76)
Current Ratio 4.07 (at or above 1.5: strong)
Debt/Equity 0.00 (at or below 0.5: strong)
P/E ratio 0.00
Fwd P/E (16.60) (negative: loss-making)
P/S ratio 14.30 (above 10: high)
P/B ratio 2.40
Past 5Y EPS Growth —
This Y EPS Growth 68.84% (at or above 15%: strong)
Next Y EPS Growth (18.41%) (below 0%: weak)
Next Y revenue growth 220.51% (at or above 10%: strong)
Next 5Y EPS Growth 57.36% (at or above 15%: strong)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

P/B against its own 10 years 72.35%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —
total individual payouts
2025 Powerpack
2024 Powerpack
2023 Powerpack
2022 Powerpack
2021 Powerpack
predictions special payouts not included in total or ratios

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 233 134 103 152
Receivables — — — —
Inventory — — — —
Other — — — —
236 136 106 155
2023 2024 2025 Q'26
Payables 5 8 4 2
ST’ Debt — — — —
Other — — — —
22 26 53 38

Compound Annual Growth %

10y 5y 3y
Sales — — —
Cash Flow — 0.00% 0.00%
Earnings — 0.00% 0.00%
Book Value — (20.21%) (29.45%)

Revenue $m

Mar Jun Sep Dec Year
’26 5 6 — — —
’25 — — 7 6 12
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (22) (16) — — —
’25 (34) (26) (19) 23 (56)
’24 (32) (23) (27) (21) (103)
’23 (30) (28) (26) (24) (107)
’22 (22) (18) (20) (23) (84)
’21 (16) (20) (22) (26) (84)
’20 (10) (9) (13) (15) (46)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (22) (16) — — —
’25 (34) (26) (19) 23 (56)
’24 (32) (23) (27) (21) (104)
’23 (31) (29) (26) (25) (111)
’22 (23) (19) (21) (23) (87)
’21 (17) (20) (22) (26) (86)
’20 (10) (9) (13) (15) (47)
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 (0.13) (0.14) — — —
’25 (0.42) (0.41) (0.26) (0.20) (1.29)
’24 (0.42) (0.46) (0.43) (0.38) (1.68)
’23 (0.58) (0.54) (0.45) (0.47) (2.02)
’22 (0.63) (0.58) (0.63) (0.60) (2.44)
’21 (0.47) (0.58) (0.66) (0.71) (2.43)
’20 (5.12) (5.50) (5.25) (0.45) (4.56)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low — — — — 23.69 10.96 3.87 1.66 0.80 0.61

Analyst estimates 2026–2028

Powerpack
High — — — — 89.06 95.38 13.40 8.57 6.80 4.22
People
People Employees — — — 51 68 116 122 128 131 79
Revenue/emp, $m — — — 0.00 0.00 0.00 0.00 0.00 0.05 0.15
Income, $m
Income, $m Revenue — — — — — — — — 7 12
Gross margin, % — — 0.00 0.00 0.00 0.00 0.00 — 100.00 100.00
EBT — — (15) (28) (57) (112) (115) (122) (127) (99)
EBT margin, % — — 0.00 0.00 0.00 0.00 0.00 0.00 (1,816.76) (819.59)
Net income — 0 (15) (28) (57) (112) (115) (122) (127) (99)
Depreciation — — 0 0 1 2 4 (2) (3) 1
Per share, $
Per share, $ Revenue — — 0.00 0.00 0.00 0.00 0.00 0.00 0.09 0.16
Earnings — — (0.34) (16.52) (4.56) (2.43) (2.44) (2.02) (1.68) (1.29)
Cash flow — — (0.30) (15.38) (3.70) (1.81) (1.77) (1.77) (1.36) (0.73)
Capex — — 0.00 (0.47) (0.05) (0.05) (0.06) (0.06) (0.01) 0.00
Free cash flow — — (0.30) (15.84) (3.75) (1.86) (1.83) (1.83) (1.37) (0.73)
Book value — — 0.32 10.20 17.00 6.21 4.13 3.93 1.73 0.89
Shares, m — — 44 2 12 46 47 60 76 77
Valuation, ×
Valuation, × P/E — — — — — — — — 0.00 0.00
P/S — — — — — — — — 0.00 11.66
P/B — — — — — — — — 0.74 3.25
EV/Sales — — — — — — — — 0.00 6.27
EV/FCF — — — — — — — — 0.35 (2.13)
Cash, $m
Cash, $m Operating cash flow — — (13) (26) (46) (84) (84) (107) (103) (56)
Capex — — (1) (1) (1) (2) (3) (4) (1) 0
Free cash flow — — (13) (26) (47) (86) (87) (111) (104) (56)
Balance, $m
Balance, $m Working capital — — 13 15 209 276 183 214 110 53
Total debt — — — 0 — 2 2 — — —
Net debt — — (16) (19) (218) (291) (202) (233) (134) (103)
Shareholders’ equity — — 14 17 212 286 195 237 131 69
Returns, %
Returns, % ROA — — (178.96) (144.06) (46.39) (42.25) (43.93) (48.91) (56.12) (62.81)
ROIC — — 0.00 0.00 0.00 0.00 0.00 (1,989.73) 0.00 0.00
ROE — — 40.72 76.47 (69.95) (44.85) (47.97) (56.33) (69.01) (99.45)
Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Prelude Therapeutics Incorporated vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
IPSC Century Therapeutics, Inc. $271.6M — (loss-making) — (loss-making) +12,667.72% (above 0%: growing) n/m +26.66% (above 0%: growing) 100.00% 0.00% Compare
EYPT EyePoint, Inc. $270.7M — (loss-making) — (loss-making) −90.49% (below 0%: shrinking) n/m +0.41% (above 0%: growing) 100.00% (19,207.10%) Compare
PALI Palisade Bio, Inc. $268.4M 2.2× — (loss-making) +19,900.00% (above 0%: growing) n/m −318.44% (below 0%: shrinking) 100.00% (2,339.60%) Compare
ABEO Abeona Therapeutics Inc. $265.9M — (loss-making) — (loss-making) +225.14% (above 0%: growing) n/m +17.11% (above 0%: growing) 63.30% (119.97%) Compare
PRLD Prelude Therapeutics Incorporated $265.0M — (loss-making) — (loss-making) +42.60% (above 0%: growing) n/m +40.32% (above 0%: growing) 100.00% (270.93%)
CABA Cabaletta Bio, Inc. $262.8M — (loss-making) — — n/m −35.72% (below 0%: shrinking) 0.00% 0.00% Compare
XFOR X4 Pharmaceuticals, Inc. $261.8M — (loss-making) — (loss-making) +346.33% (above 0%: growing) n/m +13.76% (above 0%: growing) 81.64% (186.13%) Compare
RCKT Rocket Pharmaceuticals, Inc. $259.1M — (loss-making) — — n/m +19.16% (above 0%: growing) 0.00% 0.00% Compare
VNDA Vanda Pharmaceuticals Inc. $256.4M — (loss-making) — (loss-making) −3.92% (below 0%: shrinking) n/m −101.02% (below 0%: shrinking) 92.95% (126.28%) Compare
Median of peers $264.3M — — +285.74% — +7.09% 87.30% (123.12%)

All 614 Biotechnology stocks →

Prelude Therapeutics Incorporated (PRLD) key facts

  • Strength: Prelude Therapeutics Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $12.1 million, up 73.4% from fiscal 2024.
  • Prelude Therapeutics Incorporated (PRLD) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
  • As of October 16, 2026, PRLD traded at $3.26, a market capitalization of $265.0 million.
  • Return on equity was −99.5% and debt-to-equity 0.00.
  • Its Altman Z-score is −6.83 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.

Prelude Therapeutics Incorporated (PRLD) Latest News

No news at this impact. Lower the threshold for more.
stockrow.com/PRLD · Data as of Jun 30, 2026 · For information only; not investment advice. · © 2026 stockrow.com